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Traumatic brain injury (TBI) is understood as an interplay between the initial injury, 
subsequent secondary injuries, and a complex host response all of which are highly 
heterogeneous. An understanding of the underlying biology suggests a number of 
windows where mechanistically inspired interventions could be targeted. Unfortunately, 
biologically plausible therapies have to-date failed to translate into clinical practice. 
While a number of stereotypical pathways are now understood to be involved, current 
clinical characterization is too crude for it to be possible to characterize the biological 
phenotype in a truly mechanistically meaningful way. In this review, we examine current 
and emerging technologies for fuller biochemical characterization by the simultaneous 
measurement of multiple, diverse biomarkers. We describe how clinically available tech-
niques such as cerebral microdialysis can be leveraged to give mechanistic insights into 
TBI pathobiology and how multiplex proteomic and metabolomic techniques can give a 
more complete description of the underlying biology. We also describe spatially resolved 
label-free multiplex techniques capable of probing structural differences in chemical 
signatures. Finally, we touch on the bioinformatics challenges that result from the acqui-
sition of such large amounts of chemical data in the search for a more mechanistically 
complete description of the TBI phenotype.
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iNTRODUCTiON
In broad terms, we understand the biology of traumatic brain injury (TBI) as being the result of an 
interplay between the biomechanics of the initial insult and resulting injury, the effects of the sub-
sequent resuscitative treatments and the host response. These latter factors are important; even the 
best available prognostic models predict only a small part of the observed variability in outcome (1). 
The host response is at least in part genetically determined and a number of stereotypical molecular 
mechanisms are implicated in the pathobiology of TBI (2). Nevertheless, the patient population is 
highly heterogeneous and our understanding of the biochemistry of how traumatic lesions go on to 
influence neural connectivity and brain function is very incomplete. An important related issue is the 
translational gap: time and again successful experimental interventions in animal models have failed 
FigURe 1 | Features of the five main experimental techniques with multiplex chemical sensing capability described in this review; microdialysis (MD), mass 
spectrometry (MS) [and mass spectrometry imaging (MSI)], nuclear magnetic resonance (NMR), and Raman spectroscopy (RS).
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to translate into clinical therapies. Even accepted resuscitative 
and intensive care strategies are blunt instruments with a wide 
range of harmful side effects (2). A more nuanced understanding 
of pathobiology is crucial if novel therapeutics and individualized 
treatment strategies are to be realized.
One possible explanation for the translational failures to date 
is that our understanding of the detailed pathological mecha-
nisms is incomplete or that our clinical phenotype is insufficiently 
refined to meaningfully characterize the biological state of the 
patient in a therapeutically meaningful way. Parallel exploration 
of mechanisms in the clinical setting through direct longitudi-
nal focal monitoring and neuroimaging, and in the laboratory 
is essential to understand the heterogeneity of TBI, identify 
biomarkers of injury evolution/restoration, refine experimental 
models, and develop neurorestorative treatments. A large number 
of techniques are now available for assessing molecular patterns 
of TBI in both the experimental and clinical setting (Figure 1). 
Current technologies, including microdialysis (MD) and various 
chemically sensitive imaging techniques [such as magnetic reso-
nance (MR) spectroscopy and positron emission tomography] 
may overlap with emerging technologies such as proteomic and 
metabolomic approaches or optical spectroscopy.
The molecular signatures generated by emerging experimental 
techniques are complex and new approaches will likely be needed 
to make sense of the large amount of data that are becoming 
available. However, in the post-genomic era, there has been an 
explosion in technologies exploiting informatics approaches to 
make the interpretation of biological “big data” tractable. These 
have had a huge impact on the discovery of both next-generation 
diagnostics and also new biomarkers for precision medicine 
approaches to research and treatment. The fundamental premise 
is that the evolutionary complexity of biological systems renders 
them difficult to comprehensively understand using only a reduc-
tionist approach. Such complexity can become tractable with the 
use of ’omics research; this term implies the study of entities in 
aggregate. Similar considerations apply to making sense of the 
large volumes of experimental data provided by novel biochemi-
cally sensitive techniques.
We will review the kinds of biochemical data that can now be 
accessed experimentally and explore possible future trends that 
will allow a better understanding of mechanisms and timing of 
disease progression and pave the way for personalized medicine 
in the treatment of TBI.
MULTiPLe-ANALYTe APPLiCATiONS  
OF CeReBRAL MD
Technical Aspects
Microdialysis allows continuous sampling of endogenous 
substances in the interstitial fluid of a target organ (e.g., the 
brain). The principles of MD have been extensively reviewed 
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elsewhere [for example, Ref. (3)]. Briefly, perfusion fluid is 
pumped through the inner tube of the MD probe, which has a 
concentric design and is semipermeable. At the tip of the probe, 
substances in the interstitial fluid of the target tissue can diffuse 
along the concentration gradient to some extent equilibrating 
with the perfusion fluid (4). The resulting dialysate is collected 
externally in vials.
Compared with the other technologies for assessing molecu-
lar patterns of TBI described in this review, MD offers several 
practical advantages. Most significantly, compounds can be 
measured semi-continuously in  vivo over several hours, days, 
or even for weeks. In addition, MD captures the molecules in 
the interstitial space at the site of their cellular actions and is, 
therefore, not subject to dilution such as occurs when sampling 
other fluids such as blood or cerebrospinal fluid (CSF). MD 
technology still has its limitations, including its focal resolution 
since MD samples very small volumes of tissue and its invasive-
ness [although the effects of catheter microtrauma are transient 
and reversible and likely of little effect compared to pathological 
processes (5)]. Moreover, MD may elicit an immune response 
resulting in altered microcirculation, blood–brain barrier (BBB) 
damage and perturbation of brain metabolism (3, 6). Another 
potential limitation of MD is relative substance recovery, an 
inherent aspect of MD sampling, which implies that substance 
concentration in the MD samples represent only a fraction of 
the total amount in the extracellular space. Recovery depends 
largely on perfusion flow rate (the lower the flow rate, the higher 
the recovery) and the length and diameter of the membrane. 
Other factors related to recovery are the diffusion coefficients 
of the various substances and their interaction with the dialysis 
membrane (3). At the typically low flow rates used in human 
MD studies (0.3  µL/min), the sampling time is sufficient for 
complete equilibration between the perfusion fluid and the 
surrounding environment to occur: recovery of small molecular 
weight substances, such as neurotransmitters and energetic 
compounds (i.e., glucose, lactate, and pyruvate) is very good. 
However, larger molecules, such as cytokines, chemokines, and 
other CNS proteins (e.g., axonal proteins), tend to have lower 
relative recoveries (7, 8). Sensitive analytical methods (i.e., 
immunoassays) are required to counteract such poor analyte 
recovery and small sample volumes, another potential limitation 
of MD. Nonetheless, protein sampling is challenging, and meth-
ods to optimize protein recovery with high cut-off membranes 
are under investigation. Serum albumin, which is widely used in 
the perfusion fluid, may be used to reduce non-specific binding 
of the proteins of interests to tubing and membranes, allowing 
consistent protein recovery (7). Another approach to improve 
MD recovery is to coat the membranes with substances (i.e., 
pluronic), again aimed at reducing protein binding (9, 10).
Over time, the MD catheter surface becomes coated with a 
biofilm due to an inevitable stereotyped inflammatory response 
to indwelling implants, and this has been demonstrated after 
8  days by electron microscopy (11). As a result, a drop-off in 
recovery in vivo may be expected (12). However, such a reduction 
in performance over time has not been consistently demonstrated 
(11) and clinical use over prolonged periods is commonplace. The 
measurement of a small diffusible molecule such as urea whose 
plasma concentration can be conveniently tracked and is related 
to brain interstitial concentration has been suggested as an indi-
cator of MD performance (13).
While MD is relatively safe, it is a highly invasive technique 
and is, therefore, intrinsically unsuitable for use in mild TBI. 
For similar reasons, it is difficult to obtain normative data from 
truly “normal” brain that limits our physiological understanding 
although MD has been applied to patients who have undergone 
elective neurosurgery in an attempt to obtain better reference 
ranges (14).
Clinical and Translational (Research) 
Applications of MD
Microdialysis was originally developed to measure cerebral 
neurotransmitters (15). Over the last decade, cerebral MD has 
been increasingly used in the clinical setting as an established 
technique for continuous monitoring of substrate delivery and 
metabolism in patients with TBI and other acute brain injuries. 
In addition, MD continues to be a powerful translational research 
tool to explore cerebral physiological and pathophysiological 
mechanisms. This topic will be the main focus of this section and 
cited studies are summarized in Table 1.
The clinical use of MD to monitor brain chemistry in neuro-
intensive care has the topic of excellent reviews (24, 25). Clinical 
bedside MD analyzers using colorimetric enzymatic assays are 
commercially available for measurement of compounds related to 
brain energy metabolism, including glucose, lactate, and pyruvate 
as well as glycerol and the amino acid glutamate, although these 
are less commonly used clinically. The lactate/pyruvate ratio 
(LPR) is commonly calculated as an indicator of failing aerobic 
metabolism and, additionally, has the advantage of being insensi-
tive to recovery fraction since both numerator and denominator 
are affected approximately equally.
Traumatic brain injury results in well defined metabolic 
disturbances (i.e., metabolic crisis) characterized by high LPR, 
high glutamate, and low glucose levels. These metabolic patterns 
may occur despite adequate resuscitation and controlled intrac-
ranial pressure (ICP) (26) and may also be associated with non-
convulsive seizures, periodic discharges, and cortical spreading 
depolarization (27, 28). Metabolic perturbation is related to 
clinical outcome and is affected by interventions (29–34). Such 
metabolic traits are of interest since the restoration of metabolic 
homeostasis is a key goal of intensive care. Elevations in LPR 
are increasingly clinically accepted as a metabolic marker with a 
potential to direct therapeutic interventions (25). However, LPR 
cannot be univocally interpreted as a sign of ischemia. Elevated 
LPR in the absence of ischemia with normal or high pyruvate 
concentration has been also described. This may reflect mito-
chondrial dysfunction (35). LPR elevation with low oxygenation 
characterizes post-TBI ischemia, whereas metabolic crisis as LPR 
elevation but with normal or high oxygenation is associated with 
profound mitochondrial dysfunction but a normal supply of 
energetic substrate. These two aspects need to be distinguished 
since augmenting oxygen and substrate delivery in the context 
of mitochondrial failure will be at best ineffective and could 
potentially be harmful.
TABLe 1 | Research applications of MD.
Reference Patients characteristics Time (after injury) Biosample Techniques employed Key findings
Magnoni et al. (8) TBI, GCS <8 (16 TBI, no 
controls)
12–96 h ECF (contusional and 
normal appearing brain)
100 kDa MD + serial ELISA (no 
sample pooling) 
Elevated tau in brain ECF correlates with reduced amyloid-β levels and predicts adverse 
clinical outcome. Tau and NFL levels were 4-fold higher in patients with MD catheters 
placed in pericontusional regions than those with MD in normal-appearing frontal lobe
Magnoni et al. (5) TBI, GCS <8, no controls 13–96 h ECF (contusional and 
normal appearing brain)
100 kDa MD + serial ELISA (no 
sample pooling) 
Acute tau in brain ECF correlated with DTI measurements of reduced brain white 
matter integrity in white matter-masked region near the MD catheter
Helmy et al. (7) TBI, GCS <8 (12 TBI, no 
controls)
<96 h–5 d ECF, plasma 100 kDa MD + Multiplex ELISA 
(sample pooling)
Cytokine production is highly compartmentalized, with quantitative and qualitative 
differences between brain parenchymal and systemic cytokine concentrations
Helmy et al. (16) TBI, GCS <8 (20 TBI, no 
controls)
24 h–5 d ECF (normal appearing 
brain), plasma
reverse 100 kDa MD + Multiplex 
ELISA (sample pooling)
Subcutaneously administered rhIL-1Ra results in a large increase in concentration 
of this cytokine both in the circulation and in the brain ECF, in TBI patients. rhIL-1Ra 
treatment modulates the brain extracellular cytokine and chemokine profile
Marklund et al. (17) TBI, GCS <8 (8 TBI, no 
controls)
1–5 d ECF 100 kDa MD + standard ELISA 
(sample pooling) 
Patients with a predominantly focal lesion show higher ECF tau than those with DAI, 
1–3 d post injury. Patients with DAI show consistently higher amyloid-β42 levels than 
those with focal injury
Guilfoyle et al. (18) TBI, GCS < 8 (12 TBI, 
controls: paired catheteters 
in normal appearing brain)
24–48 h to 5 d ECF (contusional and 
normal appearing brain)
100 kDa MD + Multiplex ELISA 
(sample pooling)
Early and localized increase in MMP-9 concentration within pericontusional brain 
post-TBI is indicative of BBB damage and edema formation
Petzold et al. (19) TBI, GCS median 9 (10 
TBI, no controls)
3 h–5 d ECF (contusional and 
normal appearing brain)
100 kDa MD + standard ELISA 
and Gel electrophoresis of 
(sample pooling) 
Quantification of specific protein biomarkers (NfH476-986 and NfH476-1026) 
applicable to in vivo monitoring of diffuse axonal injury and neuronal loss in TBI
Lakshmanan  
et al. (20)
TBI, GCS <8, or a GCS of 
9–14 with contusion on CT 
scan. (2 TBI with normal 
LPR and 3 with LPR >40.)
<4 d ECF(contusional and 
normal appearing 
brain), serum
20 kDa MD + peptidomics and 
proteomics approaches based on 
different MS platforms (MALDI–
TOF MS, LC-MS/MS) 
Quantification of protein fragments in the ECF. Metabolic distress after TBI is 
associated with a differential proteome that indicates cellular destruction during 
the acute phase. This suggests that metabolic stress has immediate cellular 
consequences after TBI
Jalloh et al. (21) TBI, GCS <8 (9 TBI) 1–7 d ECF (normal appearing) Reverse 100 kDa MD with 
13C-labeled compounds + ex vivo 
NMR of 13C-labeled metabolites 
Lower lactate/pyruvate ratio suggests better redox status: cytosolic NADH recycled 
to NAD+ by mitochondrial shuttles. Direct tricarboxylic acid cycle supplementation 
with 2,3-13C2 succinate improved TBI brain chemistry, indicated by biomarkers and 
13C-labeling patterns in metabolites
Orešicˇ et al. (22) TBI, GCS <8 (5 TBI, no 
controls)
Acutely after TBI ECF, serum 100 kDa MD + MS-based 
metabolomics 
(GC × GC-TOF-MS)
TBI is associated with a specific metabolic profile in serum which is also reflected in 
brain ECF (MD samples), which is exacerbated proportionally to the severity of TBI. 
Top ranking serum metabolites associated with TBI were found highly correlated 
with their MD levels suggesting possible sensitivity to BBB damage, as well as 
protective response and altered metabolism post-TBI
Reference injury model 
characteristics
Time (after injury) Biosample Techniques employed Key findings
Dahlin et al. (23) Model of progressive ICP 
increase leading to brain 
death (swine) 
<12 h ECF 100 kDa MD + proteomics by 
iTRAQ and nanoflow LC-MS/MS 
(sample pooling) 
Definition of in vivo performance of a refined MD method, including catheter surface 
modification, for protein biomarker sampling in a clinically relevant porcine brain 
injury model. Surface modified MD show improved extraction efficiency for most of 
the proteins compared to naïve MD catheters
Patient characteristics describes the injury severity level according to GCS, and the number of patients/controls included in the study. Injury model characteristics describes the experimental TBI model used. Time after injury refers 
to the sampling time point/s or window. Biosample specifies the sample used for the analysis. Techniques employed describes the technique and/or assay used for the analysis. Key findings highlight any specific insights or notable 
findings in the papers.
BBB, blood–brain barrier; CT, computed tomography; d, day/s; DAI, diffuse axonal injury; DTI, diffusion tensor imaging; ECF, extracellular fluid; ELISA, enzyme-linked immunosorbent assay; GC, gas chromatography; GCS, Glasgow 
coma scale; h, hour/s; ICP, intracranial pressure; iTRAQ, isobaric tags for relative and absolute quantification; LC, liquid chromatography; LPR, lactate pyruvate ratio; MALDI, matrix-assisted laser desorption/ionization;  
MD, microdialysis; MMP-9, matrix metallopeptidase 9; MS, mass spectrometry; NAD+, nicotinamide adenine dinucleotide (oxidized form); NADH, Nicotinamide adenine dinucleotide (reduced form); NfH, neurofilament heavy chain; 
NFL, neurofilament light chain; NMR, nuclear magnetic resonance; rhIL-1Ra, recombinant human interleukin-1 receptor antagonist; TBI, traumatic brain injury; TOF, time of flight.
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Microdialysis is also currently the only technique for measur-
ing the concentration of putative neuroprotective drugs directly 
in the brain parenchyma of patients in clinical pharmacological 
studies (36). Helmy et  al. used this technique to demonstrate 
cerebral penetration of an interleukin-1 receptor antagonist and 
explore its biological effects by downstream MD sampling of 
cytokines and chemokines (16). Similarly, Mazzeo et al. used MD 
to assess the effect of cyclosporin on brain energy metabolism 
in a randomized, double blind, placebo-controlled study on 50 
patients with severe brain injury (37).
Novel, elegant studies have combined 13C-labeled MD and 
detection with ex vivo nuclear magnetic resonance (NMR) or 
in  vivo MR spectroscopy to provide insights into important 
biochemical pathways in the human brain (38). Notably, these 
studies provided evidence that lactate can be used as substrate 
in vivo and that direct tricarboxylic acid cycle supplementation 
with 2,3-13C2 succinate improves brain chemistry after TBI (21). 
Both the pharmacological and labeling studies are examples of 
novel translational medicine approaches to the mechanistic 
investigation of putative therapeutic strategies and neuroprotec-
tive drugs. Along similar lines, pilot interventional studies have 
used MD to demonstrate beneficial effects of exogenous lactate 
supplementation in patients with TBI (30).
Microdialysis may also be used to measure in  vivo changes 
in protein biomarker concentrations after TBI (9, 25, 39). Such 
studies require catheters with a higher permeability cutoff. 
Colloids such as dextran or albumin solutions are usually added 
to the standard perfusion fluid to increase both fluid and pro-
tein recovery (7, 10). The small volumes collected by standard 
hourly sampling (at 0.3  µL/min flow rate) are rarely sufficient 
to measure biomarkers of interest using standard ELISA tech-
niques. Samples may be pooled, but this reduces time resolution 
(17). Alternatively, high sensitivity ELISA, multiplex approaches 
(i.e., Luminex technology) and sequential ELISA methods 
(where, instead of discarding the solution after incubation, a 
portion is sequentially transferred to further ELISA plates with 
different antibodies so that unbound analytes can be captured) 
have been applied in an attempt to overcome this limitation and 
measure several biomarkers simultaneously with the traditional 
hourly or two-hourly sampling frequency (7, 8, 18). There is a 
limit to the number of biomarkers that can be simultaneously 
measured from the same sample. However, proximity ligation 
assay (PLA) and proximity extension assay (PEA) technologies 
are currently being investigated for the simultaneous analysis of 
more than 100 biomarkers in MD samples (9). PLA technology 
has superior sensitivity compared to conventional sandwich 
assays, and it is likely that this methodology will confer a signifi-
cantly better time resolution.
Recent MD studies have showed that the brain extracellular 
fluid contains increased concentrations of tau, neurofilament 
light chain (NF-L), and neurofilament heavy chain (NF-H), all of 
which are normally cytosolic axonal proteins (8, 17, 19) but which 
may be released into the extracellular space after TBI as result of 
axonal injury. Magnoni et al. placed MD catheters in 16 patients 
with severe TBI and demonstrated the feasibility of quantitative 
assessment of the axonal proteins NF-L and tau with a 1–2 h time 
resolution. Importantly, they also found a positive correlation 
between initial tau levels and poor clinical outcome, likely reflect-
ing the degree of axonal injury (8). Comparable results have also 
been obtained from measuring tau with standard ELISA, albeit 
with reduced time sensitivity (17). Similarly, Petzold et al. used 
high cut-off MD to measure the levels of extracellular fluid NF-H 
fragments and monitor diffuse axonal injury and neuronal loss 
in vivo after TBI (19). These MD-based assessments of biomark-
ers of TBI require further validation but could be useful for early 
phase clinical pharmacodynamic testing of candidate therapeu-
tics targeting axonal injury after TBI. Current technology is not 
suitable for bedside application. However, improvements to the 
speed and sensitivity of protein biomarker measurements may 
change this landscape in the near future. Future studies using 
methods such as rapid biomarker sampling combined with 
enhanced analytical techniques and/or novel pharmacological 
tools could provide additional information on the importance 
of tau and other proteins in both the acute pathophysiology and 
long-term consequences of TBI.
Helmy et al. used MD to characterize the cytokine signatures 
after severe TBI in 12 patients over 5  days using an analytical 
multiplex approach (i.e., Luminex technology) (7, 40). Forty-two 
cytokines were measured. Notably, the extracellular fluid con-
centrations of several of the explored cytokines were significantly 
higher than plasma concentrations and showed a stereotyped 
temporal peak, indicating local production.
Several matrix metalloproteinases (MMPs) have also been 
measured in MD samples from paired MD catheters in pericon-
tusional vs radiologically “normal” sites using a multi-analyte 
profiling kit. For proteins detection, 8-h samples were pooled 
together. This study showed that MMP-9 concentrations are 
increased in pericontusional brain early post-TBI, likely reflect-
ing post- traumatic proteolytic breakdown of the BBB which cor-
relates with hemorrhagic progression and vasogenic edema (18).
At present, clinical MD bedside analyzers employ simple 
colorimetric assays for the quantification of energetic-related 
molecules. Bedside MD assessment of protein biomarkers with 
similarly convenient automated immunoassays would be very 
attractive for TBI research and translation into clinical practice, 
when available (41).
MD Combined with Proteomics  
and Metabolomics
One new application of MD is in the comparison of protein 
and metabolic profiles of extracellular fluids in healthy and 
diseased subjects using proteomic and metabolomic approaches. 
Compared to classical detection methods, proteomics and 
metabolomics do not limit the number of molecules simultane-
ously analyzed. Proteomic studies using MD samples are techni-
cally challenging and the MD membrane pore-size represents 
one intrinsic limitation. Nonetheless, recovery of substances 
larger than the formal cut-off value has also been observed in 
proteomic studies of human brain microdialysate using clinical 
20 kDa (42) and research 100 kDa catheters in an experimental 
study (23). In these studies, proteins larger than the formal cut-
off value crossed the dialysis membrane to a significant extent 
although true concentrations in the extracellular fluid are likely 
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to be underestimated. One important technical consideration 
is that it is impossible to use albumin in the perfusate, which is 
common using high cut-off MD catheters, as albumin masks the 
other proteins in the proteomic analysis.
Lakshmanan and coworkers developed another possible 
application of MD/proteomics by comparing microdialysate 
samples of TBI patients with normal and abnormal metabolism 
as evidenced by the LPR threshold of 40 (20). They pursued a 
diagnostic and biomarkers identification approach by combin-
ing peptidomics profiling [by matrix-assisted laser desorption/
ionization (MALDI)-MS] with classical bottom-up proteomics 
profiling (LC–MS/MS). They identified differential proteomic 
changes (i.e., 13 unique proteins) in the cerebral microdialysate 
of patients with abnormal metabolism as compared to the control 
group. These proteins consisted of cytoarchitectural proteins, 
as well as blood breakdown proteins and a few mitochondrial 
proteins.
Another interesting application of metabolic MD profiling 
has been performed by Orešič et  al. Applying an untargeted 
metabolomics strategy based on GCxGC TOF-MS platform, 
microdialysate was analyzed from 12 samples acquired from 
4 TBI patients to study the potential relevance of the serum 
metabolic profiles in TBI to brain metabolism (22). Interestingly, 
the top ranking serum metabolites associated with TBI were 
found highly correlated with their MD levels suggesting possible 
sensitivity to disruption of the BBB. Among these metabolites 
were sugar derivatives, metabolites related to energy metabolism 
as well as several hydroxy-acids. Notably, the medium-chain fatty 
acids (MCFA, C7–C10) were detected at relatively high concen-
trations in MD as compared to their corresponding concentra-
tions in blood, while the long-chain fatty acids had lower levels 
in MD than in blood.
MULTiPLeX CHeMiCAL PROFiLiNg
While MD is convenient for measuring temporal profiles, its 
application is typically limited to sampling relatively small panels 
of markers that can be recovered from the interstitial space. 
In reality, biochemical changes following TBI are complex and 
heterogeneous so a more mechanistically complete description 
requires the use of techniques capable of the sensitive detection 
of a great number of analytes simultaneously in any particular 
biosample of interest. Mass spectrometry (MS) is a key analytical 
platform capable of multiplex analysis of a wide variety of sample 
types and underpins the emerging technologies of proteomics 
and metabolomics. It provides quantitative molecular data and 
can be used either for the untargeted exploratory identification of 
hundreds of proteins and metabolites or alternatively in a focused 
way for the quantification of a small number of known molecular 
features (either proteins or metabolites) with a sensitivity of down 
to the parts-per-billion level.
A mass spectrometer measures the mass-to charge ratio [m/z] 
of gas-phase ions. Briefly, the sample of interest is first volatilized 
and ionized in the ion-source. During the ionization process, 
molecules may break down into a range of smaller fragments 
with characteristic charges and masses. The resultant ions are 
then sorted according to their m/z ratio by a mass analyzer. 
Different ionization techniques and mass analyzers are now 
available with varying cost and performance (43). There are many 
different modes of MS analysis ranging from semi-quantitative 
untargeted methods employing high-resolution instruments 
or quantitative/targeted analysis (44–46). MS instruments may 
be coupled to liquid phase pre-separation methods such as 
liquid chromatography (LC-MS), capillary electrophoresis or ion 
mobi lity separation to enhance the dynamic range, sensitivity, 
specificity, and chemical coverage (47–49). Off-line separation 
techniques (e.g., CAX-PAGE, SDS-PAGE) can be also employed, 
especially for protein/peptide separation. Given the chemical 
diversity of proteins and metabolites and the high sensitivity of 
this technology, MS has proven its superiority in metabolomics 
and proteomics. Interested readers are referred to several excel-
lent reviews on the basics of MS and its application in ’omics 
strategies (50).
Proteomics
Proteomics is the study of the proteome; a set of “all proteins 
encoded by the genome” (51). Protein expression is highly 
dynamic, changing in response to environmental stimuli and 
with the progression of a disease. With advances in technol-
ogy, neuroproteomics “a dedicated discipline for the study of the 
expression, interaction and function of proteins in the nervous 
system” has rapidly grown, contributing to the elucidation of the 
mechanisms of neurological diseases and to the identification of 
potential biomarkers of injury (52–58). Proteins already identi-
fied as having the sensitivity and specificity to be used as clinical 
biomarkers of TBI include S100B, neuron-specific enolase (NSE), 
ubiquitin C-terminal hydrolase L1 (UCH-L1), glial fibrillary 
acid protein (GFAP) myelin basic protein, cleaved tau protein, 
spectrin breakdown products (SBDPs), and NFL (53, 59–63). 
Panels of biomarkers may be needed to provide a more accurate 
and complete description of the pathology (53, 64–66) and could 
help in patients stratification, selection of treatment strategies, 
and outcome prediction (53, 56, 67). The application of combined 
neuroproteomics/neurosystems biology analysis in characteriz-
ing dynamic/spatial protein changes and interactions in response 
to injury is discussed below and cited studies are summarized in 
Table 2. Excellent reviews are available for complete analysis of 
these aspects (57, 67, 68).
Due to the complex and heterogeneous biology of TBI, the 
analysis and interpretation of the resultant proteome needs to 
account for both spatial and temporal changes. For example, 
proteins that increase in abundance within the neocortex may 
decrease within the hippocampus of controlled cortically injured 
(CCI) rats (79). Moreover, age-related changes in particular 
proteins are reported after TBI (79), supportive of “the vulner-
ability of older patients and resilience of younger ones in recovery 
after brain injuries.” Using a label free quantitative platform, 
Cortes et al. (77) showed that sub-cellular protein translocation 
and alternative isoform translation occurred in the neocortical 
tissue from a CCI rat model at 48 h post-injury. They observed 
the membrane-dissociation of vinculin, a membrane-cytoskeletal 
protein involved in anchoring actin to the plasma membrane, 
after injury. Increased cytosolic vinculin might suggest destabi-
lization and retraction of neuronal processes. Furthermore, they 
TABLe 2 | MS-based proteomics.
Reference Patients 
characteristics
Time 
(after 
injury)
Biosample Techniques 
employed
Proteomics 
platform
Key findings
Conti et al. (69) Severe TBI, 
GCS < 7 (6 TBI 
vs 6 controls)
<12 h CSF Proteomics 2-DE and MALDI-
TOF MS
Upregulation of acute phase response proteins 
(A1AT, HPT1β, α1/2, and tetramer), presence of FDP
Hanrieder et al. (70) Severe TBI  
(3 TBI, no 
controls)
<9 d CSF Proteomics iTRAQ + nanoflow 
LC coupled off-line to 
MS/MS
Temporal profile of protein changes in CSF 
showing changes in acute phase proteins but also 
brain specific proteins such as GFAP and NSE
Harish et al. (71) Mild, moderate, 
and severe TBI 
(26 TBI patients, 
30 TBI autopsy 
cases)
<4 d 
(when 
available)
Brain tissue 
(biopsy or 
autopsy)
Proteomics; electron 
microscopy; 
energy metabolism, 
cytokine, 
antioxidant, and lipid 
peroxidation assays; 
western blot 
iTRAQ + SCX 
LC-MS/MS
Contusional and pericontusional tissues exhibit 
different proteomic signatures
Hergenroeder  
et al. (64, 65)
Severe TBI, 
GCS ≤ 8  
(11 TBI vs  
11 controls)
<3 d Serum Proteomics iTRAQ + LC-MS/MS CRP and SAA increase in serum after TBI.  
In contrast RBP4 was reduced
Sjödin et al. (72) TBI (2 TBI,  
no controls)
NA CSF Proteomics ProteoMiner 
protein enrichment 
technology based 
on HLL, OFFGEL 
isoelectric focusing 
of tryptic peptides, 
LC-MS/MS
HLL strategy enriched low abundant protein 
biomarkers in human CSF and increased the 
number of detected proteins. Well characterized 
proteins in TBI, i.e., NSE, GFAP, MBP, CK-B, and 
S-100β were successfully identified
Xu et al. (73) Severe TBI, 
GCS ≤ 8 
(12 TBI vs 8 
controls)
<3 d Brain tissue 
(biopsy or 
autopsy)
Proteomics, western 
blot
2-plex TMT labeling 
and LC-MS/MS
Overexpression of proteins involved in glial 
cell differentiation, immune regulation and 
apolipoprotein catalysis in the statin pathway
Yang et al. (74) Severe TBI, 
GCS ≤ 8 
(11 TBI vs 2 
controls)
<8 h Brain tissue 
(biopsy-frontal 
cortex-)
Proteomics 2-DE and MALDI-
TOF MS
Temporal changes of overall protein expression 
in TBI (at <3h, 4–6 h and 6–8 h post-TBI) and 
controls. Significantly changed proteins were 
mainly involved in metabolism, protein synthesis 
and turnover, electron transport, cytoskeleton 
proteins, signaling transduction, stress response, 
and cell cycle
Gao et al. (75) Pediatric iTBI 
(13 TBI vs 
controls)
<24 h 
post 
hospital 
admission
CSF Proteomics, western 
blot
Two-dimensional 
DIGE, MALDI-MS and 
LC-MS/MS
HP levels lower in iTBI compared to non-inflicted 
TBI. PGDS and CC levels was higher in iTBI 
compared to non-inflicted TBI
Haqqani et al. (76) Pediatric severe 
TBI, GCS ≤8  
(6 TBI, no 
controls)
<8 h post 
injury
Serum Proteomics, ELISA ICAT nanoLC-MS/MS Differentially expressed proteins involved in 
inflammation, innate immunity, and early stress/
defense response (e.g., Toll receptors, signaling 
kinases, transcription factors, proteases, protein 
involved in response to oxidative-stress)
Reference injury model 
characteristics
Time 
(after 
injury)
Biosample Techniques 
employed
Proteomics 
platform
Key findings
Cortes et al. (77) CCI (rat) 2 d Brain tissue 
(pericontusional 
cortex)
Proteomics 2D-LC/ion mobility 
IMS/orthogonal 
TOF-MS
Assessment of protein dynamics and 
traslocations, including vinculin whose cytosolic 
traslocation suggests destabilization and 
retraction of neuronal processes
Crawford et al. (78) CCI (mouse) 
mild and severe 
24 h, 1, 
or 3 m
Plasma Proteomics, ELISA iTRAQ + LC–MS/MS Modulation of protein functional clusters related to 
acute phase response, oxidative stress, and lipid 
metabolism as function of TBI and in response to 
TBI*APOE genotype
(Continued)
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Reference injury model 
characteristics
Time 
(after 
injury)
Biosample Techniques 
employed
Proteomics 
platform
Key findings
Kobeissy et al. (57) CCI (rat) 1–7 d Brain tissue 
(ipsilateral 
cortex)
Proteomics CAX-PAGE and 
LC–MS/MS 
Decreased abundance of MMIF, aconitase, 
SOD, NF, and CaM. Increased abundance in 
complement C3, Pin1, elongation factor 2, and 
PACSIN
Mehan and  
Strauss (79),
CCI (rat) in 
aged, young 
adults, and 
juveniles
3 d Brain tissue 
(parietal 
cortex and 
hippocampus)
Proteomics, western 
blot, behavioral tests
2-DE and 
MALDI-TOF-MS
Modulation of 15 proteins isoforms in relation 
to age and injury in cortex after TBI. Among 
these: Two isoforms of HSP27, which changed 
with age, were upregulated in response to 
injury and showed interactions age*injury; BSA 
was increased in juveniles only and showed an 
age*injury interaction; ApoE showed an age*injury 
interaction
Wu et al. (80) FP (rat) 4 d Brain tissue 
(hippocampus)
Proteomics, western 
blot
18O-water differential 
labeling and 
multidimensional 
tandem LC-MS/MS
Downregulation of 76 proteins at 4 d after TBI 
mainly related to energy metabolism, oxidative 
phosphorylation, electron transport chain, 
calcium signaling and homeostasis. An important 
downregulation of CANB1 was observed in TBI 
rats.
Patient characteristics describe the injury severity level according to GCS and the number of patients/controls included in the study. Injury model characteristics describes the 
experimental TBI model (and species) used and the injury severity (if available). Time after injury illustrates the sampling time point/s or window. Biosample specifies the sample used 
for the analysis. Techniques employed describe the technique and/or assay used for the analysis. Key findings highlight any specific insights or notable findings in the papers.
2-DE, two-dimensional gel electrophoresis; A1AT, α1 antitrypsin; ADP, adenosine diphosphate; APOE, apolipoprotein E; ATP, adenosine triphosphate; BSA, bovine serum albumin; 
CaM, calmodulin; CANB1, calcineurin B; CAX-PAGE, cation–anion exchange chromatography-1D SDS gel electrophoresis; CC, cystatin C; CCI, controlled cortical impact; CK-B, 
creatine kinase B-type; CRP, c-reactive protein; CSF, cerebrospinal fluid; d, day/s; DIGE, difference in gel electrophoresis; ELISA, enzyme-linked immunosorbent assay; FDP, 
fibrin degradation product; FP, fluid percussion; GFAP, glial fibrillary acid protein; GCS, Glasgow coma scale; h, hour/s; HLL, hexapeptide ligand libraries; HP, haptoglobin; HPT1β 
and α2/1, haptoglobin 1 β, α2, and α1; HSP27, heat shock protein 27; ICAT, Isotope-Coded Affinity Tag; IMS, ion mobility spectrometry; iTBI, inflicted TBI; iTRAQ, Isobaric Tags 
for Relative and Absolute Quantitation; LC, liquid chromatography; LC–MS/MS, liquid chromatography-tandem mass spectrometry; m, month/s; MALDI, matrix-assisted laser 
desorption/ionization; MBP, myelin basic protein; MMIF, macrophage migration inhibitory factor; MS, mass spectrometry; NA, not available; NF, neurofascin; NSE, neuron-specific 
enolase; PACSIN, protein kinase C and casein kinase substrate in neurons protein 1; PDGS, prostaglandin D2 synthase; Pin1, peptidyl-prolyl cis-trans isomerase A; RBP4, retinol 
binding protein 4; SAA, serum amyloid A; SCX, strong cation exchange; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide gel electrophoresis; SOD, superoxide dismutase;  
TBI, traumatic brain injury; TMT, tandem mass tag; TOF, time-of-flight; MS, mass spectrometry.
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highlighted the relevance of protein isoforms (e.g., neurofascin) 
within the TBI-responsive proteome. Wu et  al. (80) used a 
sophisticated stable isotope 18O-water differential labeling and 
multidimensional LC–MS to profile the proteomic response at 
4 days-post TBI in the CA3 sub-region of the rat hippocampus 
rather than the global hippocampus. They proposed a calcineurin 
compensatory model conferring protection from extensive TBI-
evoked down regulation of energetics and aberrant regulation 
of proteins responsible of synaptic structures/reorganization, 
paving the way for the “identification of novel therapeutic targets 
for cognitive rescue in TBI.”
Traumatic brain injury pathobiology evolves over time and 
biomarker kinetics after injury is a critical factor in their clinical 
interpretation (81, 82). Crawford and colleagues used a quanti-
tative proteomic strategy (iTRAQ-LC/MS) to observe a panel of 
plasma proteins varying in their temporal profile (24 h, 1, and 
3 months) in response to the severity of injury in a CCI mouse 
model of mild and severe brain injury. At 24  h post-injury, 
proteomic changes were greater in the mild than severe injury 
group, suggesting a more complex acute molecular response. 
In addition, there was greater overlap in protein regulation 
between the time points in the mild group, indicating that dif-
ferent temporal profile of protein involvement can be associated 
with the nature of severe injury (78). Bioinformatic analysis of 
modulated proteins identified particular biological modules 
associated with TBI, mainly related to the acute phase response, 
oxidative stress, and lipid metabolism.
Kobeissy et al. (57) recently reported an in-depth description 
of the dynamic changes in global neuroproteome between acute 
(1  day post-TBI) and subacute (7  days post-TBI) TBI in rats 
using the cation–anion exchange chromatography-1D SDS gel 
electrophoresis (CAX-PAGE) LC–MS/MS platform. Importantly 
the authors employed systems biology strategies to infer time-
dependent changes in cellular pathways caused by TBI. Proteins 
involved in cell migration, mitochondrial damage, neuronal 
toxicity, and heat shock response were uniquely altered at 24 h 
post TBI, while others related to regeneration, axon guidance, 
axonogenesis, cell growth, and differentiation were solely altered 
at 7  days post-CCI. Of interest among a total of 19 proteins 
showing increase in abundance in both acute and subacute TBI 
samples, the C3 complement component showed a progressive 
increase over time. C3 is acute phase protein with key systemic 
and brain local immune regulatory functions; it can be easily 
measured in biofluids and could represent a promising candidate 
marker in TBI.
The minimal/lack of availability of brain tissue TBI and 
control specimens is an obstacle to obtaining direct information 
on the brain injury processes. Below we describe some of the 
proteomic studies that have analyzed human brain tissue, CSF 
or plasma in TBI patients to show how biospecimen selection 
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represents a major challenge in characterizing pathology. Yang 
et al. (74) investigated how the timing may influence the human 
brain cortex protein expression profile in 11 patients needing 
craniotomy. Using a traditional proteomic approach (protein 
separation by bi-dimensional electrophoresis followed by 
MALDI-MS-TOF for identification), levels of injury-associated 
proteins were minimal in the first 3  h after injury, increasing 
to a maximum at 4–6  h before declining again at 8  h. The 
functions of the significantly changed proteins were mainly 
related to metabolism, electron transport, signal transduction, 
cytoskeletal integrity, stress response, transport, protein synthe-
sis, and turnover. Harish et  al. (71) postulated that structural 
brain characteristics may lead to differences in TBI response 
and analyzed the proteomic profiles of human contusional and 
pericontusional tissue (26 individuals) using an advanced tech-
nique with improved quantitative accuracy (iTRAQ-LC–MS/
MS). The contusional tissue was mainly characterized by altered 
immune response, and synaptic and mitochondrial dysfunction, 
while the pericontusional tissue displayed altered regulation of 
neurogenesis, cytoskeletal architecture, and vesicle proteins. 
The characteristic signatures of two anatomically adjacent yet 
distinct regions might help in the mechanistic understanding 
of injury evaluation. Again, the use of advanced MS-proteomics 
techniques allowed to identify more than 4,000 proteins in the 
cerebral parenchyma of post-TBI patients, showing significant 
alterations in myelin proteins, complement activation, and 
apolipoproteins (73).
Cerebrospinal fluid and plasma/serum also contain molecu-
lar patterns related to the CNS and are alternative biospecimens 
with higher clinical translational opportunities. CSF is the most 
representative being in direct contact with the brain particularly 
in instances where the BBB has been breached. However, protein 
concentrations vary widely between CSF samples from different 
TBI patients (55). Plasma/serum samples are easier to acquire 
than CSF and may have a high overall protein concentration. 
Furthermore, since blood sampling is safe and well tolerated, 
normal control data are simple to obtain and such analysis 
can additionally be applicable to mild TBI where the risks of 
more invasive techniques are proportionately harder to jus-
tify. However, plasma proteins have a wide dynamic range of 
concentrations, where the presence highly abundant blood-
born housekeeping proteins can hinder the discovery of specific 
proteomic patterns of interest. The analysis of serum proteins 
is further complicated by extracranial or systemic influences 
since protein signatures are generally not completely unique 
to the CNS. Moreover, proteomics patterns found in the CSF 
are not straightforwardly translatable to blood. Indeed it has 
been reported that there is only a partial overlap between 
plasma and CSF proteome (83). One of the first investigations 
demonstrating the feasibility of a proteomic strategy to study 
the CSF from TBI patients was performed by Conti et al. (69) 
using a conventional gel-based proteomic strategy (2-DE and 
MALDI-TOF-MS) to profile CSF from a small number patients 
and matched control subjects. Elevated fibrinolysis markers 
were detected, probably because of blood coagulation after TBI. 
A similar approach was used to compare the CSF profile from 
inflicted (n = 13) and non-inflicted TBI (n = 13) in pediatric 
patients with severe injury (75). Increased expression of hapto-
globin, prostaglandin synthase, and cystatin were found within 
24 h of injury. Another study on CSF (72) performed protein 
enrichment using hexapeptide ligand libraries to reduce protein 
dynamic range so as to pick-up low abundance CSF proteins. 
This small proof-of-concept study with only two subjects found 
proteins associated with degeneration/regeneration, including 
NSE and GFAP. An interesting time-resolved neuroproteomic 
study on post-traumatic human ventricular CSF (70) revealed 
significant temporal changes in the levels of acute phase proteins 
as well as brain specific proteins (e.g., NSE, GFAP) with a pattern 
of change between days 3 and 5 indicating sensitivity to second-
ary events concordant with medical records in a small number 
of patients. Observations such as these suggest that proteomic 
analysis may also provide evidence of, and mechanistic insights 
into, secondary injury. It is noteworthy that the abovementioned 
CSF proteomic studies also strengthened the use of serum GFAP 
and NSE as potential prognostic markers for TBI as previously 
suggested (84, 85).
Although plasma/serum is very clinically convenient, it has 
been little used in mechanistic-based proteomics studies of TBI. 
Proteins changes generated in the brain after TBI may potentially 
migrate into blood but in doing so are greatly diluted. Moreover, 
plasma and serum proteomics is a challenging task due to the 
large dynamic range of protein concentration, being 99% of their 
proteome comprised of 20 highly abundant proteins (86). Despite 
these hurdles, recent implementation in MS platforms has been 
essential for the proteomics study of TBI using human plasma/
serum.
A feasibility study by Haqqani et al. (76) using isotope-coded 
affinity tag-based proteomics, identified differences in 95 serum 
proteins (within 8 h of admission) between six pediatric severe 
TBI patients and matched controls. These proteins were mainly 
involved in inflammation and innate immunity indicating a mas-
sive defense response. Several of these serum proteins, such as 
α-spectrin, NSE, tau, and amyloid-A, were likely of brain-origin. 
In addition, several proteins showed quantitative changes similar 
to those of S100B, an established serum biomarker of TBI, sug-
gesting that pattern behavior of a group of proteins can help in 
gaining information about disease characteristics and in the 
discovery of relevant peripheral TBI biomarkers.
The same technique was used to screen the serum of 11 adult 
severe TBI patients and matched controls (64, 65). Several pro-
teins altered after injury were in keeping with those identified by 
Haqqani in pediatric patients, including serum amyloid-A and 
retinol-binding-protein-4. Interestingly, serum amyloid-A was 
proposed as indicator of injury severity together with C-reactive 
protein, whereas retinol-binding-protein-4 was postulated as a 
predictor of ICP elevation, an important contributor to death/
disability following TBI. The authors suggested that possible 
combination of proteins, each with their own diagnostic window, 
may help identifying TBI patients who are likely to experience 
adverse secondary events such as elevation in ICP.
So far, the few clinical proteomics investigations performed 
on peripheral blood have replicated and strengthened the find-
ings from targeted analysis of specific candidate proteins as TBI 
biomarkers, recapitulating key features of the neuropathology 
TABLe 3 | MS-based metabolomics.
Reference Patients 
characteristics
Time (after 
injury)
Biosample Techniques 
employed
Proteomics 
platform
Key findings
Dash et al. (90) Mild (GSC >12) and 
severe (GSC <8) TBI 
(mild TBI, n = 20; 
severe TBI, n = 20; 
healthy volunteers 
n = 20)
<24 h Plasma MS-based 
metabolomics, 
ELISA
LC–MS and 
GC-MS
Levels of methionine, SAM, betaine, and 
2-methylglycine lower in TBI patients compared to 
controls, indicating decreased metabolism through 
the transmethylation cycle. Precursors for generation 
of glutathione, cysteine and glycine also found to 
be decreased as were intermediate metabolites of 
the gamma-glutamyl cycle (gamma-glutamyl amino 
acids and 5-oxoproline). In mild TBI patients, levels 
of methionine, a-ketobutyrate, 2 hydroxybutyrate 
and glycine decreased, albeit to lesser degrees than 
detected in the severe TBI group
Emmerich et al. (91) Soldiers with mild TBI 
(n = 21), PTSD (n = 34), 
TBI + PTSD (n = 13) 
and healthy controls 
(n = 52)
Chronic 
time point
Whole blood, 
plasma
Genotyping 
APOE, MS-based 
lipidomics 
LC–MS/MS PL levels decreased in TBI, PSD (moderate-to-severe) 
and TBI + PSD compared to controls. MUFA-
containing PC and PI species decreased in TBI and 
TBI + PTSD groups but not in PTSD subjects, ether 
PC levels were lower in PTSD and TBI + PTSD 
compared to controls. Within PC and PE classes, ratio 
of AA- to DHA-containing species decreased in mTBI. 
APOE ε4 + subjects exhibited higher PL levels 
Jeter et al. (92) Mild (GCS >12) and 
severe (GCS ≤8) TBI 
(mild TBI n = 18, severe 
TBI n = 20; healthy 
volunteers n = 20, 
orthopedic injury 
without TBI n = 15)
<24 h Plasma MS-based target 
metabolomics
LC–MS and 
GC-MS
Plasma levels of arginine, citrulline, ornithine, and 
hydroxyproline decreased in severe TBI compared to 
mild TBI or orthopedic injury. Levels of plasma creatine 
increased in severe TBI compared to healthy and 
orthopedic injury subjects. Creatine lower in severe TBI 
patients that developed high ICP compared to those 
who did not
Jeter et al. (60) Mild (GCS <12) and 
severe (GCS ≤8) TBI 
<24 h Plasma MS-based 
metabolomics
LC–MS and 
GC-MS
Levels of BCAAs (valine, isoleucine, and leucine) 
decreased in TBI compared to healthy volunteers and 
patients with orthopedic injury. Only plasma levels of 
methylglutarylcarnitine were increased after severe 
TBI. BCAAs plasma levels were similar in mild TBI and 
orthopedic patients but lower compared to healthy 
volunteers
(Continued)
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seen in humans. However, the novel protein patterns identi-
fied in these studies are not yet been validated in independent 
studies.
Metabolomics
Metabolomics refers to the study of metabolome, which has 
been defined as “the complete set of metabolites/low-molecular-
weight intermediates (<1000Da), which are context dependent, 
varying according to the physiology, developmental or pathologi-
cal state of the cell, tissue, organ or organism” (87). The techni-
cal ability to measure thousands of endogenous metabolites 
simultaneously as signatures that cellular processes leave 
behind makes metabolomics an emerging strategy in system 
biology (88, 89). The application of combined metabolomics/
neurosystems biology analysis in characterizing dynamic/
spatial metabolic signature in response to injury is discussed 
below and cited studies summarized in Table  3. Hence, 
metabolomics studies are very promising for understanding 
complex and multifactorial syndromes and may be a suitable 
starting point toward personalized medicine.
There are two general analytical approaches to metabolomic 
analysis. Targeted metabolomics refers to the detection and 
precise quantification (nM, or mg/mL) of a small set of known 
compounds. It is a hypothesis-driven approach, where then set of 
metabolites related to one or more pathways is already defined. 
A limitation of the targeted approach is that it requires the 
compounds of interest to be known a priori and to be available 
in their purified form. The untargeted approach (“metabolite 
fingerprinting”) is instead data driven and is used for complete 
metabolome comparison (i.e., as many metabolites as possible are 
measured) (88).
The most common analytical instrumentations used in 
metabolomics are MS or NMR spectroscopy. Both techniques 
have advantages and disadvantages, briefly mentioned here and 
the reader is referred to a number of excellent review articles 
describing the technology involved (88, 98, 99).
Mass spectrometry is sensitive to ionizable compounds down 
to the picomolar range. Such high sensitivity makes MS-based 
methods powerful tools especially in targeted studies when the 
absolute quantification of groups of metabolites is the goal. In 
Reference Patients 
characteristics
Time (after 
injury)
Biosample Techniques 
employed
Proteomics 
platform
Key findings
Orešicˇ et al. (22) TBI, GCS ≤8 (5 TBI, no 
controls)
Acutely 
after TBI
ECF, serum 100 kDa MD 
and MS-based 
metabolomics 
GC × GC- 
TOF-MS
Two medium-chain fatty acids (decanoic and 
octanoic acids) and sugar derivatives including 
2,3-bisphosphoglyceric acid are strongly associated 
with TBI severity. Serum metabolic profile also reflected 
in brain ECF (MD samples). Top ranking serum 
metabolites associated with TBI were found highly 
correlated with their MD levels suggesting possible 
sensitivity to BBB damage, as well as protective 
response and altered metabolism post-TBI
Yi et al. (93) Moderate to severe TBI 
(72 TBI patients with 
cognitive deficits, 31 
TBI patients without 
cognitive deficits, 67 
healthy controls)
<12 h Serum MS-based 
metabolomics
GC-MS A serum metabolites panel consisting of serine, 
pyroglutamic acid, phenylalanine, galactose, palmitic 
acid, arachidonic acid, linoleic acid, citric acid, and 
2,3,4-trihydroxybutyrate was identified to be able 
to discriminate between TBI patients with cognitive 
impairment, TBI patients without cognitive impairment 
and healthy controls
Reference injury model 
characteristics
Time (after 
injury)
Biosample Techniques 
employed
Proteomics 
platform
Key findings
Abdullah et al. (94) Severe CCI (mouse) 3 m Hippocampus, 
cortex, 
cerebellum 
(left and right) 
and plasma
Behavioral tests, 
MS-based 
lipidomics
LC-MS/MS Total PC-, SM-, and PE-species increased in 
hippocampus but decreased in cortex and cerebella 
of TBI mice compared to controls. Total PL levels 
decreased in plasma of TBI mice. Ether-PC in the 
cerebella and ether-PE in cortex decreased in TBI 
mice. PUFA-containing PC and PE species, particularly 
ratios of DHA to arachidonic acid decreased in the 
hippocampi, cortex, and plasma of TBI mice
Bahado-Singh 
et al. (95)
WDI (mouse) 4 h and 1 d Serum Target 
quantitative 
metabolomics
Biocrates 
platform 
with FIA and 
LC–MS/MS
Thirty-six of 150 measured metabolites were different 
in TBI compared to control mice. Temporal changes 
(from 4 to 24 h) were observed in 56 metabolites 
after TBI. The combination of six metabolites 
achieved complete accuracy for distinguishing early 
TBI (4 h) from late TBI (24 h) with spermidine as the 
most discriminating biomarker. Affected pathway 
included arginine, proline, glutathione, cysteine, and 
sphingolipid metabolism pathways
Emmerich et al. (96) CHI (mouse) 1 d; 3, 6 m; 
1 and 2 y
Plasma MS-based 
lipidomics, ELISA
HILIC 
LC-MS/MS
PC, PE, PI, and SM levels decreased with aging. PC, 
LPC, PE, LPE and PI (but not SM) were decreased at 
3 months post-TBI, and all classes were decreased 
at 24 months post-TBI compared to controls. Total 
lipid peroxidation was elevated at 3 months post-
TBI compared to control when PUFA levels were 
decreased.
Sheth et al. (97) mild and severe TBI 
(rat), tMCAo (mouse), 
acute stroke (9 stroke 
patients, 5 stroke-mimic 
patients)
TBI and 
tMCAo: 4 h, 
1, 2, and 
7 d. Stroke 
patients: 
within 
3 h from 
the first 
symptom
brain tissue 
(only mice and 
rats), plasma, 
sphingolipids 
extraction
TTC, 
immunostaining, 
MRI, target 
MS-based 
lipidomics
LC-MS/MS TBI: 56 SLs species were present at higher 
concentration in brain compared to plasma. SL 
increased in plasma from 6 to 24 h post TBI with SM 
increase proportional to CCI severity. tMCAo: 45 SLs 
species were present at higher concentration in brain 
compared to plasma. SL increased in plasma from 6 to 
24 h post tMCAo with SM and Cer showing the largest 
relative changes. SM + Cer defined the SL score. Stroke 
patients: within 3 h post-stroke, SL score was higher 
than in stroke-mimic patients. The SL score correlated 
with the volume of ischemic brain tissue by MRI
Patient characteristics describe the injury severity level according to GCS, and the number of patients/controls included in the study. Injury model characteristics describe the 
experimental TBI model used and the injury severity (if available). Time after injury illustrates the sampling time point/s or window. Biosample specifies the sample used for the 
analysis. Techniques employed describe the technique and/or assay used for the analysis. Key findings highlight any specific insights or notable findings in the papers.
AA, arachidonic acid; APOE, apolipoprotein E; BBB, blood–brain barrier; BCAAs, branched-chain amino acids; CCI, controlled cortical impact; Cer, Ceramides; CHI, closed head 
injury; d, day/s; DHA, docosahexaenoic acid; ECF, extracellular fluid; ELISA, enzyme-linked immunosorbent assay; FIA, flow injection analysis; GC, gas chromatography; GCS, 
Glasgow coma scale; h, hour/s; HILIC, hydrophilic interaction chromatography; ICP, intracranial pressure; LC, liquid chromatography; m, month/s; MD, microdialysis;  
MRI, magnetic resonance imaging; MS, mass spectrometry; MUFA, mono-unsaturated fatty acids; PC, phosphatidylcholine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; 
PL, phospholipids; PTSD, post-traumatic stress disorder; PUFA, polyunsaturated fatty acid; SAM, S-adenosylmethionine; SLs, sphingolipids; SM, sphingomyelin; TBI, traumatic 
brain injury; tMCAo, transient middle cerebral artery occlusion; TTC, 2,3,5-triphenyltetrazolium chloride; WDI, weight drop injury; y, year/s.
TABLe 3 | Continued
11
Ercole et al. Probing Molecular Signatures of TBI
Frontiers in Neurology | www.frontiersin.org August 2017 | Volume 8 | Article 450
12
Ercole et al. Probing Molecular Signatures of TBI
Frontiers in Neurology | www.frontiersin.org August 2017 | Volume 8 | Article 450
exploratory approaches, it can be challenging to identify hun-
dreds of metabolites simultaneously with the same efficiency for 
technical and computational reasons (100). NMR spectroscopy 
is used to identify and quantify compounds in solution that are 
MR detectable. Despite being less sensitive than MS (micromolar 
range), NMR is sample-non-destructive and it is highly repro-
ducible (101).
The study of small molecules that enter biochemical pathways 
has a long history in TBI research. For example, glucose and 
lactate dynamics have been studied with respect to TBI outcome, 
disease progression, and mechanisms (102, 103). What distin-
guishes contemporary studies is the technologies available for 
the simultaneous analysis of many metabolites in a given sample. 
Metabolomics has been applied to the diagnosis/prognosis of 
many diseases from cancer to diabetes to cardiovascular patholo-
gies (104–106) and is now an active area of research in TBI. In 
this section, we will focus on most recent TBI metabolomics 
investigations based on MS technologies applied to preclinical 
models and clinical settings as well.
Although, in recent years, there has been a much needed 
influx of TBI metabolomics studies due to various confound-
ing variables (e.g., selection biases, genetics, diet) and practical 
limitations (e.g., chronic effects of repeated mild TBI and 
ethical considerations), animal models are still important for the 
exploration of metabolic signatures of TBI for the development 
of potentially translatable approaches in both the detection and 
clinical monitoring of patients.
Since lipids and phospholipids (PLs) play important roles in 
the structural and functional integrity of neuronal membranes, 
vesicular trafficking and in neuroinflammatory responses (91, 
107–109), many investigators have focused in identifying lipid 
abnormalities associated with TBI (“lipidomics”).
Disturbances of lipid profiles in a fluid percussion injury 
(FPI) rat model of TBI have been known since the 1990s (110) 
and are a consequence of activating the phospatidylinositol 
4,5-bisphospate (PIP2) signal transduction pathway in injured 
brain. Similar findings were reported for another rat CCI model 
where free fatty acids (FFA) and diacylglycerol (DAG) levels were 
increased in the sensorimotors cortex and cerebellum of injured 
rats compared to sham animals (111).
Using a similar model of TBI, Abdullah et al. (94), used LC–
MS to investigate the PLs profiles in mice 3 months post-injury 
and reported decreased ether phosphatidylethanolamines (ePE) 
levels in the cortices and plasma of injured animals. Moreover 
polyunsaturated fatty-acid (PUFA)-containing phosphatidylcho-
line (PC) and PE species were lower in the hippocampus, cortex, 
and plasma of injured mice, thus indicating that TBI affects both 
brain and plasma PL levels, with plausible roles in the inflamma-
tory response.
Recent advances in MS techniques have allowed the develop-
ment of approaches focused on specific lipid subsets permitting 
in-depth analysis of lipids species (112). By targeting lipid profil-
ing to sphingolipids (SL), Sheth et al. (97) showed large increases 
in many circulating SL following TBI in rats, with sphingomyelins 
(SM) being the most prominent species and larger lesions pro-
duced proportionately larger increases. Since increases in many 
SLs species were also noted in plasma of mice after stroke and a 
linear correlation between circulating SLs and infarct volume was 
observed in stroke patients with neurological deficits, the authors 
suggested that lipid subset can be used as biomarkers of brain 
injury.
Phospholipid abnormalities may persist long after the initial 
injury, as reported in a closed head injury (CHI) mouse model of 
TBI (96). By using HILIC LC/MS techniques, it was shown that 
saturated, mono-unsaturated fatty acids (MUFA) and PUFA were 
differently regulated over time and ePE species were elevated at 
24 h after TBI and decreased relative to controls at chronic stages 
(3, 6, 12, and 24 months post-injury). Such longitudinal profile 
could potentially serve not only as surrogate diagnostic marker 
but also might enable the discovery of molecular targets for preci-
sion medicine.
Tracking changes in the serum metabolome to profile on-
going damage was also addressed recently by Bahado-Singh et al. 
(95) using a targeted quantitative MS platform in a mouse model 
of TBI. Arginine and proline pathway, glutathione metabolism, 
SL metabolism, and polyamine pathways changed significantly 
over time suggesting their potential utility for ascertaining the 
timing of TBI and for monitoring the degree of oxidative injury 
and associated neuronal damage.
Clinical evidence of PL involvement in TBI has been available 
for some time (113, 114), in that increased glycerol (an indicator 
of PL degradation) concentration is found in the CSF dialysate 
from brain-injured patients and during the first 24 h in subjects 
with an unfavorable outcome after severe TBI (115). A cross-
sectional study reported that patients with TBI had increased 
PL within their CSF relative to control subjects (116). Moreover, 
CSF levels of PC and PE were enhanced in patients who did not 
survived following severe TBI compared to those who survived 
(115). Although not really lipidomic studies, they pointed to a 
possible association between brain PL disturbances and TBI and 
paved the way to more sophisticated analyses to deep insight the 
role of lipid classes in TBI pathophysiology.
Detectable PL disturbances in the CSF suggests that such sig-
nals might also be detected in peripheral biofluids. In reality, the 
interplay between brain and systemic lipid metabolism is com-
plex. In fact, the brain can synthesize saturated (SFA) and MUFA 
containing PL species; whereas PUFA are transported from blood 
to brain, where they serve many functions (e.g., membrane repair 
and lipid mediators) (117).
By using an MS-based lipidomic platform able to qualitatively 
and qualitatively analyze several 100 PL species and their degree 
of saturation, Emmerich et al. (91) screened a large cohort of mili-
tary personnel (120 subjects) and found that PL species profiling, 
together with APO-E genotyping, was helpful to differentiate 
mild TBI and post-traumatic disorder, whose diagnosis is often 
difficult because of overlapping symptomatology.
Interestingly, exploiting a sophisticated metabolomic platform 
based on 2-dimensional gas chromatography coupled to high 
resolution MS (GCxGC-TOF-MS) Orešič et al. (22) showed that 
two MCFAs increased in serum from a large set of TBI patients 
(144 subjects) and this was strongly associated with the severity 
of TBI. The accumulation of MCFA might be particularly intrigu-
ing due to their role in fatty acid oxidation disorders (118). Thus, 
MCFA variations may inform on mitochondrial dysfunction in 
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TBI. Sugar derivatives and hydroxyl acids were also upregulated 
in the serum of TBI patients, suggestive of BBB disruption and 
disturbed energetics. Outcome prediction was further improved 
when the metabolite dataset was combined with clinical and 
imaging variables.
As expected, changes in several other circulating metabolites 
may also contribute to the “TBI metabotype.” Differences in 
plasma levels of l-arginine and its key metabolic products have 
been found between severe and mild TBI patients (92). l-arginine 
is involved in metabolic pathways critical for cerebral blood flow 
(CBF) regulation and extracellular matrix (ECM) remodeling 
(119), thus authors speculated that alteration in circulating arigi-
nine found in severe TBI patients may contribute to brain injury 
such as decreased CBF and collagen synthesis.
Cognitive impairment is one of the most significant TBI-
associated disabilities (120). TBI patients with and without cogni-
tive impairment, and healthy controls could be discriminated by 
a panel of serum metabolites (serine, pyroglutamic acid, pheny-
lalanine, galactose, palmitic acid, arachidonic acid, linoleic acid, 
citric acid, and 2,3,4-trihydroxybutyrate), identified by GC-MS, 
although the study was small (93). Nevertheless, post-TBI cogni-
tive impairment was associated with altered metabolism of amino 
acids, carbohydrates, and lipids. The detrimental role of lipid 
dyregulation during neurodevelopment and repair after TBI was 
suggested by the altered levels of arachidonic acid (increased) and 
palmitic acid (decreased) TBI patients with cognitive impairment 
(121, 122). Indeed, arachidonic acid, a pro-inflammatory and oxi-
dative lipid species, was also found to be significantly increased 
in serum from TBI subjects (123, 124) and was associated with 
platelet dysfunction following TBI (125).
A targeted metabolomic study showed that branched chain 
amino acids (BCAA) concentration was decreased in TBI patients 
(60) although this was not confirmed by Orešič et al. (22) prob-
ably due to the high variability in BCAA levels. A further targeted 
metabolomic investigation, based on a combination of LC–MS 
and GC-MS techniques, reported that severe TBI patients have 
low levels of plasma methionine and its metabolic products (e.g., 
S-adenosylmethionine, 2 methylglycine) and their decrease may 
contribute to brain injury pathology (90). However, caution has 
to be exercised when considering circulating dietary amino acids 
such as methionine, when diet intake is not controlled for.
NOveL SPATiALLY ReSOLveD 
TeCHNOLOgieS
The proteomic and metabolomic/lipidomic techniques described 
thus far rely on global measurements from a particular body 
compartment. However, chemical changes occur over spatial 
length scales that can reach down to the sub-cellular level and are 
dynamic over time. To further understand biochemical events at 
a local tissue or even cellular level, a spatial mapping is required 
and imaging plays an important role. Traditionally, this has been 
achieved via immunohistochemical or other labeling techniques. 
However, in the context of the ’omics paradigm presented, such 
labeling techniques are restricting as they typically probe only a 
few different species at a time and can only be applied to ex vivo 
tissue sections. A label-free spatially resolved technique yielding 
pleiotropic chemical information would be highly desirable, 
particularly if this could be achieved in a non-destructive way 
that could ultimately be deployed in vivo.
Mass Spectrometry imaging (MSi)
For accurately understanding the pathological condition of a 
tissue such as brain, which has many functional compartments 
it is not only necessary to determine the spectrum of molecular 
features involved in the processes, but also to visualize their spa-
tial distribution within the tissue. MSI is one of the latest rapidly 
growing techniques for the identification and spatial localization 
of molecules in tissues (126, 127). MALDI is the most common 
ionization techniques used in MSI. Ions are produced directly 
from a tissue slice coated with MALDI matrix and sequential 
masses are acquired across the tissue surface (128). In a typical 
MALDI-MSI experiment “a tissue section is deposited on a steel 
plate, sprayed with a matrix solution and analysed by MALDI-
MSI. The distribution of biomolecules on a tissue section can be 
readily visualized in two-dimensions, assigning to each pixel the ion 
intensity specific for the molecule under study” (129).
Mass spectrometry imaging permits the simultaneous visua-
lization of many types of molecules such as small molecule 
drugs, metabolites, peptides, proteins, and lipids. Since MSI is a 
label-free technique that provides the possibility to combine tis-
sue histological data with MS ones it represents a powerful tool 
for visualizing simultaneously the distribution of molecules in 
relation to tissue heterogeneity and its pathological status (130).
Experimental TBI studies revealed that the cortex, hippocam-
pus, and thalamus are selectively vulnerable to injury (131–134). 
Previous studies reported alterations in the lipid profile as an 
important contributor to this vulnerability and the evolution of 
secondary damage in TBI (135–137). Consequently, efforts have 
been made in determining spatial distribution of altered lipid 
profile in response to brain injury using MSI.
In a study assessing lipid changes in response to blast-induced 
mild TBI, major increases in ganglioside GM2 were noted in the 
hippocampus, thalamus, and hypothalamus after a single blast 
exposure (138). A concomitant decrease in ceramides was also 
noted in the same study. Hankin et al. (139) showed changes in 
lysophosphatidylcholine, PC, PE, and SM that were specific to 
their adduct ions in response to ischemia/reperfusion injury in the 
brain. By using an innovative silver nanoparticle protocol, Roux 
et al. (140) imaged rat brain lipids over time (1, 3, and 7 days), 
in a CCI model of TBI. Their results indicated that increases in 
SM and ceramide were already detectable 1 day post-TBI in the 
injured cortex. In addition, changes in derivatives of DAGs, cho-
lesteryl esters, PE, and PI were noted at later time points (days 3 
and 7 post-TBI). The kinetic differences in lipid classes might give 
an insight into the time-course of injury response and remodeling 
of injured brain tissue.
A biochemical map of critical mitochondrial PL species of car-
diolipin (CL) in several anatomical brain regions from a CCI rat 
model of TBI was recently provided by Sparvero et al. (141). The 
authors demonstrated that regional/spatial CL decrease occurred 
not only within the contusion but also in the hippocampal and 
thalamic regions, distant from the site of injury. They proposed 
that the specific decreases in CL, which will ultimately influence 
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mitochondrial efficiency, “may constitute an upstream mechanism 
for CL-driven signalling in different brain regions as an early response 
mechanism and may underlie the bioenergetic changes after TBI.”
Optical Spectroscopy
Optical spectroscopy reveals a chemical fingerprint of any given 
sample, based on specific absorption of different colors of light by 
different molecular bonds. Analogous to masses held together by 
springs, energy absorbed from incident light by molecular bonds 
can generate vibrations and rotations, such as stretching, torsion, 
or bending, depending on the molecule. The frequencies of such 
“modes” of oscillation are determined by the nature of the inter-
atomic forces and are, therefore, characteristic to the bond. The 
frequencies and geometries of permissible modes are governed 
by quantum mechanical considerations and are dependent on 
the detailed electronic configurations and symmetry of the bonds 
in question. Cellular components such as lipids, proteins, and 
nucleic acids consist of many bonds and, thus, as a whole, pro-
vide a rich chemical fingerprint, particularly for frequencies in 
the infra-red (IR) part of the electromagnetic spectrum. Optical 
spectroscopic techniques are advantageous for chemical analysis 
as they are non-destructive; can be easily integrated with imaging; 
and, in principle, can be easily translated to in vivo applications.
Raman spectroscopy (RS) provides a chemical fingerprint 
based solely on vibrational interactions with tissue. The chemical 
information obtained from RS is similar to that obtained by IR 
spectroscopy (although symmetry and charge considerations 
mean that not all Raman active modes are IR active and vice versa). 
The Raman effect is very weak but high sensitivity can be achieved 
locally by focusing the probe beam via a microscope arrange-
ment onto the sample being analyzed and using high sensitivity 
detection instrumentation. The relatively low-cost availability of 
stable and compact high intensity laser light sources has greatly 
facilitated this technique. However, heating of the sample limits 
the signal to noise improvements that can be achieved by simply 
increasing the incident laser power for biological specimens.
Raman spectroscopy has been applied to models of brain injury 
from radiation (142) and penetrating trauma (143) as well as in 
a model of peripheral nerve injury (144). More recently, RS has 
been used to characterize chemical progression and resolution in 
a model of focal TBI (145). Raman spectra were recorded from 
various regions in the cortex in contusional and pericontusional 
tissue as well as from the contralateral hemisphere in specimens 
taken at 2 and 7 days post injury as well as from sham controls. 
Significant differences in chemical spectra were seen. Most 
significantly, there were differences in protein signal, including 
strong changes from heme associated with acute hemorrhage 
at the contusion site at 2  days. Hemorrhagic conversion is an 
important and devastating process, and one that may directly 
contribute to cytotoxic and oxidative damage (146). This heme 
signal was found to have resolved by 7 days consistent with the 
phagocytic clearance of hemoglobin and heme by macrophages/
microglia. Furthermore, the authors found differences in lipid 
composition—in particular an elevation in cholesterol signal 
relative to PL at both 2 and 7 days at the site of the contusion and 
in pericontusional tissue. This lipid sensitivity of RS is particularly 
attractive given the importance of lipid metabolism in neuronal 
degeneration and repair and, in particular, the upregulation of 
cholesterol transport after injury since this material is critical for 
cellular repair. The ratio of particular Raman peaks relating to 
the relative concentration of β-sheet protein has previously been 
suggested as being sensitive to amyloid and has been studied in 
“cleaner” systems such as the eye lens (147). The authors observed 
changes in this signal after TBI also. However, there is generally 
substantial overlap between lipid and protein signals, which can 
make these observations difficult to interpret with certainty. 
Acquisition of spectra from pure reference compounds can 
reduce uncertainty and assist with identification of some specific 
lipid and protein contributions, such as those described above. 
Furthermore, overall changes in lipid and protein concentration 
are easily detectable and relevant to the disease biology. This lipid 
and protein sensitivity makes RS a promising technology for 
research into key pathways of interest after TBI. A key advantage 
of RS is the potential for imaging and it is possible to demonstrate 
spatial changes in both protein and lipid chemistry.
While RS is a multiplexed technique, the related technique 
of coherent anti-stokes Raman scattering (CARS) allows the 
targeted examination and imaging of particular Raman bands 
with high sensitivity and has been employed in areas allied to 
TBI, such as the study of myelin degradation processes where it 
has revealed a calcium-dependent pathway in a spinal cord model 
of demyelination (148).
Raman spectroscopy is a label-free and non-destructive tech-
nique. RS and allied techniques such as CARS show considerable 
promise as both untargeted and targeted chemically sensitive 
imaging techniques. If the spatial resolution is sacrificed, in prin-
ciple, it is possible to miniaturize the equipment and perform RS 
in vivo via implanted fiber-optic probes offering the possibility of 
a continuous multiplex assessment of chemistry. Although the RS 
signal is weak, it increases with the fourth-power of incident light 
frequency and so signals using green or blue laser illumination are 
far stronger and have better signal to noise than can be achieved 
with conventional red or IR illumination. However, these fre-
quencies can also excite tissue autofluorescence, which interferes 
with the baseline of the Raman spectrum making quantitative 
analysis more difficult. Although a nuisance for RS, flavoproteins 
such as NADH exhibit strong redox-sensitive fluorescence signals 
offering the possibility of simultaneous interrogation of the status 
of the electron transport chain.
FUTURe CHALLeNgeS iN TBi ’OMiCS: 
OPPORTUNiTieS FOR SYSTeM BiOLOgY
The flurry of research in TBI ’omics over the last decade is prom-
ising but many issues have to be addressed before deciphering 
complex molecular patterns that define TBI biochemistry. The 
limited sample sizes studied to date, differences in sample col-
lection protocols, in outcome measures and limited number of 
longitudinal clinical designs are hindering the assessment of 
patient ’omics trajectories. A better tracking of protein dynamics 
and range of post-translational signaling events are also needed. 
The development of multiplexing quantitative targeted proteom-
ics would help in choosing the most specific candidates from the 
wide range of potential protein biomarkers found in the literature 
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and in moving into clinical validation and assay development. 
Such approaches could complement the use of conventional pro-
teins biomarkers assays and provide a new framework to develop 
and optimize interventions. The analytical technology will need 
to be further refined if clinical applications are to ultimately be 
realized as current experimental techniques are too cumbersome 
for bedside use. Cost is a further consideration: experimental 
assays are expensive both in terms of equipment and consuma-
bles. While this is perhaps less of a limitation in the intensive care 
unit where treatment costs are already significant, it is a particular 
problem for applications in mild/moderate TBI and the benefits 
in terms of treatment would need to be significant in order to 
be justifiable with current technology. Having said this, bioas-
say technology is advancing continuously and there are many 
potential applications of clinical metabolomics and proteomics 
outside TBI driving advances, so the future landscape is likely to 
look very different.
While metabolic changes are fundamental to TBI patho-
physiology and metabolomic signatures may contain prognostic 
information, it remains unclear if these metabolic changes 
are causative or just a consequence of TBI pathophysiology. 
Moreover, further studies are needed to determine to what extent 
observed metabolic profiles are brain specific or whether they 
reflect interactions with systemic changes.
The fast-growing ’omics domain have been facilitated by 
advances in analytical technology such as various MS modali-
ties or future optical spectroscopic methods and are generating 
a massive amount of molecular data, offering the identification 
and quantification of hundreds of molecules involved in diverse 
cellular pathways and, therefore, their consequent phenotypes. 
The complexity of biological systems and large number of 
variables coupled with the relatively low number of observations 
(e.g., samples) make integrative analyses challenging. One of the 
greatest challenges is that of TBI bioinformatics. The develop-
ment of easy-to-use informatics software was required to leverage 
genomic data and similar information technology developments 
will need to take place before proteomic and metabolomic/
lipidomic data can be fully exploited. Progress is being made in 
developing novel analytical techniques (149, 150). However, the 
challenges are significant as the data are far more complex than 
is the case for genetics. A paucity of specialized mathematical, 
statistical, and bioinformatics tools and the need of consider-
able computational effort hampers rapid progress in the field 
(151–153).
Recently, Feala and colleagues elegantly addressed this issue in 
TBI research (53) with the suggestion that existing TBI data sets 
available from the literature could be exploited. They compiled a 
list of proteins candidates from the TBI literature and by applying 
network and pathway analysis, were able to generate candidate 
new biomarkers. From their integrative network analysis, the pro-
tein kinase ABL1 was particularly appealing being already known 
as tractable target by imatinib in chronic myeloid leukemia.
Functional interpretation of proteins or metabolites usually 
includes enrichment analysis and pathway analysis that often 
overlap as both work by comparing significant features, identi-
fied by different statistical workflows, to predefined knowledge 
databases. To this purpose, many tools exist either free (e.g., 
MetaboAnalyst,) or on the market (e.g., MetaCore™ from 
Thompson Reuters; IPA from Qiagen) with their own advantages 
and drawbacks.
One possibility for a truly comprehensive characterization of 
TBI might consists in simultaneously monitoring the levels of 
transcripts/proteins/metabolites from the same study popula-
tion and in combining the resulting multilevel data to infer the 
dynamics of the underlying biological networks.
Multiomic integration—the full knowledge of the proteome/
metabolome and its spatio-temporal evolution after TBI—would 
be a powerful insight into the underlying pathobiology. However, 
the goal of omics techniques is not simply to catalog all the 
transcripts, proteins, and metabolites; rather it is to understand 
biological mechanisms. To do this, it is necessary to map metabo-
lomic and proteomic data onto known pathways.
The abovementioned software (MetaCore; IPA) and others, 
such as InCRoMAP (154), 3Omics (155), IMPaAa (156), already 
allow the mapping of different molecular features (gene, miRNA, 
protein, metabolite) into biological pathways as networks of 
interconnected nodes, allowing their visualization for the easy 
identification of relationships and hidden patterns for hypothesis 
generation. Recently, network approaches have been used to relate 
genomic and proteomic signatures in cellular pathways pertinent 
to experimental TBI-related cellular systems (157).
However, there are still open challenges in ’omics data integra-
tion (including dimensionality, heterogeneity, data source and 
processing, computational power, and capacity) that need to be 
faced to take effective advantage of new experimental multilayer 
data. Moreover, given the complexity of TBI, only a comprehen-
sive and integrated analysis of molecular data with clinical meas-
urements may help to plan an early and appropriate intervention 
in TBI. In this context, incorporation of ’omics data into clinical 
practice may, thus, provides a means to establish new therapeutic 
targets and to follow individual patient response to therapy. Data 
mining and machine learning approaches are now representing 
a very powerful tool since they can be used to develop classifica-
tion models and to elucidate early multilevel markers signatures 
which could reveal the biological pathways involved in disease 
progression (101, 158–160).
Future sophisticated systems biology approaches may allow 
TBI researchers to make biological sense of the vast quantity of 
data now available in order to identify novel therapeutic targets 
and assess the effectiveness of treatments or alternatively, through 
correlation with population cohorts, to realize a precision medi-
cine approach through the intelligent targeting of interventions 
to patients in whom they may be most effective.
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